Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 239

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 239
---
 compounds are smaller than we believe they are, our revenues
    may be adversely impacted, and our business may suffer;

    ●
    Government price
    controls or other changes in pricing regulation could restrict the amount that we are able to charge for CC8464, CT2000 and
    CT3000, if approved, or any of our other future compounds that may be approved in the future, which would adversely affect
    our revenue and results of operations;

    ●
    If we are unable
    to obtain and maintain adequate U.S. and foreign patent protection for our compounds, including CC8464, CT2000 and CT3000,
    or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize
    products and technologies similar or identical to ours, and our ability to successfully commercialize CC8464, CT2000, CT3000
    and any of our other current or future compounds may be adversely affected; 

    ●
    We could issue “blank
    check” preferred stock without stockholder approval with the effect of diluting then current stockholder interests and
    impairing their voting rights; and provisions in our charter documents could discourage a takeover that stockholders may consider
    favorable;

    ●
    Our articles of
    incorporation (which, as may be amended and/or restated, we refer to as our “articles of incorporation”) designate
    the Second Judicial District Court, in and for the State of Nevada, located in Washoe County, Nevada, as the exclusive forum
    for certain types of actions and proceedings that may be initiated by our stockholders, which could limit stockholders’
    ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents;

    ●
    The other factors
    set forth under “Risk Factors.”

These
and other risks are more fully described in the section entitled “Risk Factors” in this Report. If any of these risks
actually occurs, our business, financial condition, results of operations, cash flows, and prospects could be materially and adversely
affected. As a result, you could lose all or part of your investment in our securities.

Risks
Related to Our Business

The
report of the independent registered public accounting firm on our 2024 and 2023 financial statements contains a going concern
qualification.

The
report of the independent registered public accounting firm covering our consolidated financial statements for the years ended
December